Epi proColon, a blood-based Septin9 gene methylation assay, was approved by the US FDA in 2016 as a CRC screening test for the average-risk population aged over 50 who are unwilling or unable to undergo colonoscopy or other recommended CRC screenings [17]. This evidence concerns the gene SEPTIN9 and colorectal carcinoma.